To test this hypothesis, we measured Apelin levels in serum samples from a cohort of 55 RCC patients that were treated for 3–5 months with sunitinib as a single agent (Appendix Fig S3A) and evaluated their progression‐free survival (PFS). The gene discussed is APLN; the disease is renal cell adenocarcinoma.